Ozenoxacin - to be deleted, duplicate

Drug Profile

Ozenoxacin - to be deleted, duplicate

Latest Information Update: 11 Sep 2015

Price : $50

At a glance

  • Originator Toyama Chemical
  • Developer Ferrer
  • Class Antibacterials; Cyclopropanes; Pyridines; Quinolones; Small molecules
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Impetigo
  • Phase II Skin and soft tissue infections

Most Recent Events

  • 30 Jul 2015 Regulatory filings are planned in Canada, USA and Europe
  • 30 Jul 2015 Ferrer completes a phase III trial in Impetigo in USA, South Africa, Puerto Rico, Spain, Germany, Romania and Russia
  • 05 May 2015 Ozenoxacin is still in phase-III development for Impetigo and phase-II development for Skin and soft tissue infections in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top